TGA approves Wegovy for reducing MACE risk
Doctors can now prescribe the GLP-1 receptor agonist for patients with overweight, established CVD and no history of diabetes.
The TGA has approved Wegovy to reduce the risk of major adverse events in patients with cardiovascular disease who are overweight or obese.
The once-weekly injectable semaglutide formulation hit Australian shelves last August, two years after it received TGA approval for weight loss.
